Table 1.

Baseline characteristics

CharacteristicsAll PatientsLosartan GroupPlacebo GroupP Value
Patients (n)1537776
Age at transplant (yr)48.7±12.449.4±11.148.0±13.60.50
Men, n (%)94 (61.4)47 (61.0)47 (61.8)1.00
White patients, n (%)133 (86.9)66 (85.7)67 (88.2)0.81
Cause of kidney disease, n (%)0.19
 Diabetes mellitus57 (37.3)28 (36.4)29 (38.2)
 Hypertension10 (6.5)8 (10.4)2 (2.6)
 Polycystic kidney disease23 (15.0)13 (16.9)10 (13.2)
 Other63 (41.2)28 (36.4)35 (46.1)
Live donor, n (%)108 (70.6)53 (68.8)55 (72.4)0.72
First transplant, n (%)132 (86.3)69 (89.6)63 (82.9)0.25
Immunosuppression, n (%)
 CNI + MMF115 (75.2)59 (76.6)56 (73.7)0.41
 CNI + sirolimus21 (13.7)8 (10.4)13 (17.1)
 Other17 (11.1)10 (13.0)7 (9.2)
Prednisone use, n (%)42 (27.4)18 (23.4)24 (31.6)0.28
Pancreas transplant, n (%)30 (19.6)15 (19.5)15 (19.7)1.00
Acute rejection between transplant and randomization, n (%)12 (7.8)7 (9.1)5 (6.6)0.77
Time to randomization (d)58.3±33.861.5±37.255.1±29.80.25
BMI (kg/m2)26.4±5.126.6±5.126.3±5.20.78
No. of HLA matches2.3±1.62.1±1.62.5±1.50.19
Cold ischemia time (h)a17.1±6.814.9±6.119.7±6.80.02
Diuretic use, n (%)
 Loop39 (25.5)20 (26.0)19 (25.0)1.00
 Thiazide12 (7.8)6 (7.8)6 (7.9)1.00
BP (mmHg)
 Systolic130.5±18.3130.1±18.1130.9±18.60.80
 Diastolic73.5±10.774.0±11.973.1±9.40.60
Panel-reactive antibodies, n (%)104 (67)52 (67)51 (67)0.54
Hemoglobin (g/dl)11.4±1.411.3±1.411.5±1.50.45
Urine albumin-to-creatinine ratio (mg/g)23.6±10.324.4±10.023.3±11.70.73
Urine protein (g/d)0.34±0.240.34±0.250.34±0.210.72
Serum creatinine (mg/dl)1.4±0.41.4±0.41.4±0.40.40
GFR (ml/min per 1.73 m2)56.1±17.055.8±18.856.4±15.00.82
VvInt/cortex0.19±0.050.19±0.040.18±0.50.35
  • Values expressed with a plus/minus sign are the mean ± SD. CNI, calcineurin inhibitor; MMP, mycophenolate mofetil; BMI, body mass index.

  • a For deceased donors.